omcpmutil 2 (R&D Systems)

R&D Systems omcpmutil 2

CD25 (IL-2Rα) and NKG2D were immobilized to individual flow cells of a sensor chip by primary amine chemistry. Serial dilutions of IL-2, mutIL-2, and <t>OMCPmutIL-2</t> were injected across each flow cell and association and dissociation phases were measured. Renditioned graphic model of protein binding (left) with experimental binding to CD25 (middle) and NKG2D (right) for wild type human IL-2 (A), mutant human (R38A, F42K) IL-2 (B), and OMCPmutIL-2 (C). Experimental binding curves are shown for a representative experiment. (D) For binding of CD25:wild-type IL-2 and OMCPmutIL-2:NKG2D experimental curves were fitted using ANABEL software and the observed binding constant (Kobs) was measured for each concentration. The plot of Kobs vs concentration is shown with the slope as the association rate (Kon) and y-axis intercept as the dissociation rate (Koff).

Omcpmutil 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/omcpmutil 2/product/R&D Systems
Average 91 stars, based on 1 article reviews

omcpmutil 2 - by Bioz Stars, 2026-03

91/100 stars

Buy from Supplier

mouse recombinant cd25 (R&D Systems)

R&D Systems mouse recombinant cd25

Structure and in vitro characterization of <t>CD25-ADC.</t> (A) Structure and (B) in vitro characterization of CD25-ADC. (i) ELISA showing binding of anti-CD25 antibody PC61 to mouse <t>recombinant</t> CD25. (ii–iv) Flow cytometry measurement of PC61 and isotype-control antibody binding to Yac-1, MC38 and CT26 cells. (v–vii) Yac-1, MC38 and CT26 cells’ viability after exposure to CD25-ADC and isotype-ADC (and the naked pyrrolobenzodiazepine-dimer SG3199 in MC38 and CT26 cell lines). MFI, median fluorescence intensity; PABA, para amino benzoic acid.

Mouse Recombinant Cd25, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse recombinant cd25/product/R&D Systems
Average 91 stars, based on 1 article reviews

mouse recombinant cd25 - by Bioz Stars, 2026-03

91/100 stars

Buy from Supplier

recombinant human anti-cd25 antibody (Creative Biolabs)

Creative Biolabs recombinant human anti-cd25 antibody

Schematic overview of our PLGA ND-based approach for enhancing NK cell cytotoxic function, (a) PLGA NDs encapsulating prostratin, a latency-reversing agent, and aCD25 were synthesized using a nanoemulsion scheme, (b) J-Lat 10.6 cells, a model of latent HIV and leukemia, treated with Pro-aCD25-ND increased <t>CD25</t> <t>expression</t> in response to released prostratin, which enables increased aCD25 binding (also released from the NDs). These effects function in concern to prime the targeted cells for enhanced NK cell-mediated killing.

Recombinant Human Anti Cd25 Antibody, supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human anti-cd25 antibody/product/Creative Biolabs
Average 90 stars, based on 1 article reviews

recombinant human anti-cd25 antibody - by Bioz Stars, 2026-03

90/100 stars

Buy from Supplier

Image Search Results

CD25 (IL-2Rα) and NKG2D were immobilized to individual flow cells of a sensor chip by primary amine chemistry. Serial dilutions of IL-2, mutIL-2, and OMCPmutIL-2 were injected across each flow cell and association and dissociation phases were measured. Renditioned graphic model of protein binding (left) with experimental binding to CD25 (middle) and NKG2D (right) for wild type human IL-2 (A), mutant human (R38A, F42K) IL-2 (B), and OMCPmutIL-2 (C). Experimental binding curves are shown for a representative experiment. (D) For binding of CD25:wild-type IL-2 and OMCPmutIL-2:NKG2D experimental curves were fitted using ANABEL software and the observed binding constant (Kobs) was measured for each concentration. The plot of Kobs vs concentration is shown with the slope as the association rate (Kon) and y-axis intercept as the dissociation rate (Koff).

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Retargeting Interleukin-2 Signaling to NKG2D-Expressing Tumor Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy

doi: 10.4049/jimmunol.2000926

Figure Lengend Snippet: CD25 (IL-2Rα) and NKG2D were immobilized to individual flow cells of a sensor chip by primary amine chemistry. Serial dilutions of IL-2, mutIL-2, and OMCPmutIL-2 were injected across each flow cell and association and dissociation phases were measured. Renditioned graphic model of protein binding (left) with experimental binding to CD25 (middle) and NKG2D (right) for wild type human IL-2 (A), mutant human (R38A, F42K) IL-2 (B), and OMCPmutIL-2 (C). Experimental binding curves are shown for a representative experiment. (D) For binding of CD25:wild-type IL-2 and OMCPmutIL-2:NKG2D experimental curves were fitted using ANABEL software and the observed binding constant (Kobs) was measured for each concentration. The plot of Kobs vs concentration is shown with the slope as the association rate (Kon) and y-axis intercept as the dissociation rate (Koff).

Article Snippet: Surface plasmon resonance (SPR) A ProteOn XPR36 instrument (BioRad) was used to determine the kinetics of interaction of WT IL-2, mutIL-2, and OMCPmutIL-2 for murine CD25 (#2438-RM, R&D systems) and murine NKG2D-Fc (#139-NK-050, R&D systems).

Techniques: Injection, Protein Binding, Binding Assay, Mutagenesis, Software, Concentration Assay

(A) Fold TIL expansion of murine B16ova -resident leucocytes. (B) Surface expression of NKG2D and IL-2R alpha chain on mouse antigen specific CD8+ T cells compared to those with ovalbumin non-reactive TCR. (C) Fold TIL expansion of Human melanoma -derived TILS in either wild-type IL-2 (blue) or OMCPmutIL-2 (red) (C). *p<.05; **p<.01, ***p<.001, NS p>.05

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Retargeting Interleukin-2 Signaling to NKG2D-Expressing Tumor Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy

doi: 10.4049/jimmunol.2000926

Figure Lengend Snippet: (A) Fold TIL expansion of murine B16ova -resident leucocytes. (B) Surface expression of NKG2D and IL-2R alpha chain on mouse antigen specific CD8+ T cells compared to those with ovalbumin non-reactive TCR. (C) Fold TIL expansion of Human melanoma -derived TILS in either wild-type IL-2 (blue) or OMCPmutIL-2 (red) (C). *p<.05; **p<.01, ***p<.001, NS p>.05

Techniques: Expressing, Derivative Assay

(A) Number of TIL leucocytes transferred into CD45.1 congenic tumor-bearing recipients after expansion in either wild-type IL-2 or OMCPmutIL-2. Flow cytometric analysis performed 24 hours after transfer. (B)Immunohistochemical analysis of B16ova tumors in wild-type C57Bl/6 mice injected with 20×106 TILs from C57Bl/6EGFP mice expanded for 2 weeks in either wild-type IL-2 or OMCPmutIL-2. Histologic evaluation performed 120 hours after transfer. (C) Relative expression, by median fluorescence intensity, of LFA-1, CD49a or CXCR3 on TIL-resident CD8+ T cells, NK cells or gamma delta T cells after 2-week expansion in IL-2 (blue) or OMCPmutIL-2 (red). (D) Relative expression, by median fluorescence intensity, of LFA-1 on TIL-resident CD8+ T cells, NK cells or γδ T cells after either MDSC or Treg depletion prior to expansion in IL-2 (blue) or OMCPmutIL-2 (red). *p<.05; **p<.01, ***p<.001, NS p>.05

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Retargeting Interleukin-2 Signaling to NKG2D-Expressing Tumor Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy

doi: 10.4049/jimmunol.2000926

Figure Lengend Snippet: (A) Number of TIL leucocytes transferred into CD45.1 congenic tumor-bearing recipients after expansion in either wild-type IL-2 or OMCPmutIL-2. Flow cytometric analysis performed 24 hours after transfer. (B)Immunohistochemical analysis of B16ova tumors in wild-type C57Bl/6 mice injected with 20×106 TILs from C57Bl/6EGFP mice expanded for 2 weeks in either wild-type IL-2 or OMCPmutIL-2. Histologic evaluation performed 120 hours after transfer. (C) Relative expression, by median fluorescence intensity, of LFA-1, CD49a or CXCR3 on TIL-resident CD8+ T cells, NK cells or gamma delta T cells after 2-week expansion in IL-2 (blue) or OMCPmutIL-2 (red). (D) Relative expression, by median fluorescence intensity, of LFA-1 on TIL-resident CD8+ T cells, NK cells or γδ T cells after either MDSC or Treg depletion prior to expansion in IL-2 (blue) or OMCPmutIL-2 (red). *p<.05; **p<.01, ***p<.001, NS p>.05

Techniques: Immunohistochemical staining, Injection, Expressing, Fluorescence

(A) NKG2D expression in CD8+ TILs. (B) Expansion of NKG2Dlow or NKG2Dhigh CD8+ T cells in OMCPmutIL-2 or wild-type IL-2. (C) Expression of NKG2D (top), perforin (middle), and FasLigand (bottom) on flow cytometrically sorted NKG2Dlow CD8+ T cells immediately post sort (black line bar open circles), after 7 days of culture in wild-type IL-2 (blue bar, open circles) or OMCPmutIL-2 (red bar, open circles). ***p<.001

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Retargeting Interleukin-2 Signaling to NKG2D-Expressing Tumor Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy

doi: 10.4049/jimmunol.2000926

Figure Lengend Snippet: (A) NKG2D expression in CD8+ TILs. (B) Expansion of NKG2Dlow or NKG2Dhigh CD8+ T cells in OMCPmutIL-2 or wild-type IL-2. (C) Expression of NKG2D (top), perforin (middle), and FasLigand (bottom) on flow cytometrically sorted NKG2Dlow CD8+ T cells immediately post sort (black line bar open circles), after 7 days of culture in wild-type IL-2 (blue bar, open circles) or OMCPmutIL-2 (red bar, open circles). ***p<.001

Techniques: Expressing

Structure and in vitro characterization of CD25-ADC. (A) Structure and (B) in vitro characterization of CD25-ADC. (i) ELISA showing binding of anti-CD25 antibody PC61 to mouse recombinant CD25. (ii–iv) Flow cytometry measurement of PC61 and isotype-control antibody binding to Yac-1, MC38 and CT26 cells. (v–vii) Yac-1, MC38 and CT26 cells’ viability after exposure to CD25-ADC and isotype-ADC (and the naked pyrrolobenzodiazepine-dimer SG3199 in MC38 and CT26 cell lines). MFI, median fluorescence intensity; PABA, para amino benzoic acid.

Journal: Journal for Immunotherapy of Cancer

Article Title: CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

doi: 10.1136/jitc-2020-000860

Figure Lengend Snippet: Structure and in vitro characterization of CD25-ADC. (A) Structure and (B) in vitro characterization of CD25-ADC. (i) ELISA showing binding of anti-CD25 antibody PC61 to mouse recombinant CD25. (ii–iv) Flow cytometry measurement of PC61 and isotype-control antibody binding to Yac-1, MC38 and CT26 cells. (v–vii) Yac-1, MC38 and CT26 cells’ viability after exposure to CD25-ADC and isotype-ADC (and the naked pyrrolobenzodiazepine-dimer SG3199 in MC38 and CT26 cell lines). MFI, median fluorescence intensity; PABA, para amino benzoic acid.

Article Snippet: Binding of PC61 to mouse recombinant CD25 (R&D Systems) was determined by ELISA, using a mouse CD25/human Fc chimeric antigen (R&D Systems) and a secondary goat antirat HRP (Jackson Immunoresearch Laboratories).

Techniques: In Vitro, Enzyme-linked Immunosorbent Assay, Binding Assay, Recombinant, Flow Cytometry, Control, Fluorescence

In vivo antitumor activity of CD25-ADC in the s.c. MC38 syngeneic model. Treatment with (i) vehicle, (ii) anti-PD-1 antibody (5 mg/kg, on days 2, 5, and 8), (iii) non-binding ADC (1 mg/kg, single dose on day 1) alone or (iv) in combination with anti-PD-1 antibody, (v–vii) CD25-ADC (0.1, 0.5, and 1 mg/kg single dose on day 1) alone or (viii–x) in combination with anti-PD-1 antibody, started at a group mean tumor volume of 103 mm 3 . Data are shown as tumor volumes (mm 3 ) over time for each individual mouse (10 mice/group). (xi) Survival of mice shown in i–x. Lines for G4, G5, G8 and G9 are overlapping.

Journal: Journal for Immunotherapy of Cancer

Article Title: CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

doi: 10.1136/jitc-2020-000860

Figure Lengend Snippet: In vivo antitumor activity of CD25-ADC in the s.c. MC38 syngeneic model. Treatment with (i) vehicle, (ii) anti-PD-1 antibody (5 mg/kg, on days 2, 5, and 8), (iii) non-binding ADC (1 mg/kg, single dose on day 1) alone or (iv) in combination with anti-PD-1 antibody, (v–vii) CD25-ADC (0.1, 0.5, and 1 mg/kg single dose on day 1) alone or (viii–x) in combination with anti-PD-1 antibody, started at a group mean tumor volume of 103 mm 3 . Data are shown as tumor volumes (mm 3 ) over time for each individual mouse (10 mice/group). (xi) Survival of mice shown in i–x. Lines for G4, G5, G8 and G9 are overlapping.

Techniques: In Vivo, Activity Assay, Binding Assay

In vivo antitumor activity of CD25-ADC in the s.c. CT26 syngeneic model. Treatment with (i) vehicle, (ii) anti-PD-1 antibody (5 mg/kg, on days 2, 5, and 8), (iii) isotype-ADC (1 mg/kg, single dose on day 1) alone or (iv) in combination with anti-PD-1 antibody, (v–vii) CD25-ADC (0.1, 0.5, and 1 mg/kg single dose on day 1) alone or (viii–x) in combination with anti-PD-1 antibody, started at a group mean tumor volume of 110 mm 3 . Data are shown as tumor volumes (mm 3 ) over time for each individual mouse (10 mice/group). (xi) Survival of mice shown in i–x.

Journal: Journal for Immunotherapy of Cancer

Article Title: CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

doi: 10.1136/jitc-2020-000860

Figure Lengend Snippet: In vivo antitumor activity of CD25-ADC in the s.c. CT26 syngeneic model. Treatment with (i) vehicle, (ii) anti-PD-1 antibody (5 mg/kg, on days 2, 5, and 8), (iii) isotype-ADC (1 mg/kg, single dose on day 1) alone or (iv) in combination with anti-PD-1 antibody, (v–vii) CD25-ADC (0.1, 0.5, and 1 mg/kg single dose on day 1) alone or (viii–x) in combination with anti-PD-1 antibody, started at a group mean tumor volume of 110 mm 3 . Data are shown as tumor volumes (mm 3 ) over time for each individual mouse (10 mice/group). (xi) Survival of mice shown in i–x.

Techniques: In Vivo, Activity Assay

Role of CD8+ T eff cells in CD25-ADC antitumor activity in the MC38 syngeneic model. Depletion of CD8+ T eff cells significantly reduces the antitumor activity of CD25-ADC. CD25-ADC was administered intraperitoneally (i.p.) at a group mean tumor volume of 89 mm 3 as a single dose on day 1 at 0.5 mg/kg alone or in combination with anti-PD-1 antibody (5 mg/kg, on days 2, 5, and 8). Anti-CD8 T-cell depleting antibody (10 mg/kg) was injected i.p. on days 0, 5, 8, and 13. Data are shown as mean tumor volumes (mm 3 ) ± SEM over time (n=10/group).

Journal: Journal for Immunotherapy of Cancer

Article Title: CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

doi: 10.1136/jitc-2020-000860

Figure Lengend Snippet: Role of CD8+ T eff cells in CD25-ADC antitumor activity in the MC38 syngeneic model. Depletion of CD8+ T eff cells significantly reduces the antitumor activity of CD25-ADC. CD25-ADC was administered intraperitoneally (i.p.) at a group mean tumor volume of 89 mm 3 as a single dose on day 1 at 0.5 mg/kg alone or in combination with anti-PD-1 antibody (5 mg/kg, on days 2, 5, and 8). Anti-CD8 T-cell depleting antibody (10 mg/kg) was injected i.p. on days 0, 5, 8, and 13. Data are shown as mean tumor volumes (mm 3 ) ± SEM over time (n=10/group).

Techniques: Activity Assay, Injection

Intratumoral T-cell immunophenotype analysis in MC38-bearing mice. (A) Absolute quantification of intratumoral T regs , CD8+ T cells and CD8+/T reg ratio following i.p. treatment with anti-PD-1 antibody or CD25-ADC or the combination of CD25-ADC and anti-PD-1. (B) Percentage of CD69+, Ki67+ and IFNγ+ tumor-infiltrating CD8+ T cells. Tumors were processed at the indicated times (days post CD25-ADC dose). Horizontal bars represent median value. Statistical differences between treatment groups were calculated using JMP 15 by the Dunn method for joint ranking. Results were considered significant when p<0.05. *, p≤0.05; **, p≤0.01. IFN, interferon.

Journal: Journal for Immunotherapy of Cancer

Article Title: CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

doi: 10.1136/jitc-2020-000860

Figure Lengend Snippet: Intratumoral T-cell immunophenotype analysis in MC38-bearing mice. (A) Absolute quantification of intratumoral T regs , CD8+ T cells and CD8+/T reg ratio following i.p. treatment with anti-PD-1 antibody or CD25-ADC or the combination of CD25-ADC and anti-PD-1. (B) Percentage of CD69+, Ki67+ and IFNγ+ tumor-infiltrating CD8+ T cells. Tumors were processed at the indicated times (days post CD25-ADC dose). Horizontal bars represent median value. Statistical differences between treatment groups were calculated using JMP 15 by the Dunn method for joint ranking. Results were considered significant when p<0.05. *, p≤0.05; **, p≤0.01. IFN, interferon.

Techniques: Quantitative Proteomics

Circulating and thymic T-cell immunophenotype analysis in MC38-bearing mice. (A) Absolute quantification of circulating T regs , CD8+ T cells and CD8+/T reg ratio following i.p. treatment with anti-PD-1 antibody or CD25-ADC or the combination of CD25-ADC and anti-PD-1. Blood was processed at the indicated times (days post CD25-ADC dose). (B) Absolute quantification of thymic T reg cells and CD8+/T reg ratio following i.p. treatment with anti-PD-1 antibody or CD25-ADC or the combination of CD25-ADC and anti-PD-1. Thymus was processed at the indicated times (days post CD25-ADC dose). Statistical differences between treatment groups were calculated using JMP 15 by the Dunn method for joint ranking. Results were considered significant when p<0.05. *, p≤0.05; **, p≤0.01.

Journal: Journal for Immunotherapy of Cancer

Article Title: CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

doi: 10.1136/jitc-2020-000860

Figure Lengend Snippet: Circulating and thymic T-cell immunophenotype analysis in MC38-bearing mice. (A) Absolute quantification of circulating T regs , CD8+ T cells and CD8+/T reg ratio following i.p. treatment with anti-PD-1 antibody or CD25-ADC or the combination of CD25-ADC and anti-PD-1. Blood was processed at the indicated times (days post CD25-ADC dose). (B) Absolute quantification of thymic T reg cells and CD8+/T reg ratio following i.p. treatment with anti-PD-1 antibody or CD25-ADC or the combination of CD25-ADC and anti-PD-1. Thymus was processed at the indicated times (days post CD25-ADC dose). Statistical differences between treatment groups were calculated using JMP 15 by the Dunn method for joint ranking. Results were considered significant when p<0.05. *, p≤0.05; **, p≤0.01.

Techniques: Quantitative Proteomics

T-cell dynamic study in non-tumor-bearing mice. Effect of CD25-ADC on the percentage of T regs and T eff levels in non-tumor-bearing mice. Female C57BL/6 mice were injected i.p. with vehicle, CD25-ADC (0.5 mg/kg), or isotype control ADC (0.5 mg/kg) on day 0. (A) Spleen, (B) lymph node, and (C) thymus were collected 4 hours post dose, and 6, 13, and 20 days post dose for T-cell immune profiling. Levels of T regs , CD8+ T, and conventional CD4+ T cells in spleen, lymph nodes, and thymus are presented as % of CD45 cells±SEM over time.

Journal: Journal for Immunotherapy of Cancer

Article Title: CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

doi: 10.1136/jitc-2020-000860

Figure Lengend Snippet: T-cell dynamic study in non-tumor-bearing mice. Effect of CD25-ADC on the percentage of T regs and T eff levels in non-tumor-bearing mice. Female C57BL/6 mice were injected i.p. with vehicle, CD25-ADC (0.5 mg/kg), or isotype control ADC (0.5 mg/kg) on day 0. (A) Spleen, (B) lymph node, and (C) thymus were collected 4 hours post dose, and 6, 13, and 20 days post dose for T-cell immune profiling. Levels of T regs , CD8+ T, and conventional CD4+ T cells in spleen, lymph nodes, and thymus are presented as % of CD45 cells±SEM over time.

Techniques: Injection, Control

Journal: Nano research

Article Title: PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function

doi: 10.1007/s12274-020-2684-1

Figure Lengend Snippet: Schematic overview of our PLGA ND-based approach for enhancing NK cell cytotoxic function, (a) PLGA NDs encapsulating prostratin, a latency-reversing agent, and aCD25 were synthesized using a nanoemulsion scheme, (b) J-Lat 10.6 cells, a model of latent HIV and leukemia, treated with Pro-aCD25-ND increased CD25 expression in response to released prostratin, which enables increased aCD25 binding (also released from the NDs). These effects function in concern to prime the targeted cells for enhanced NK cell-mediated killing.

Article Snippet: Recombinant human anti-CD25 antibody was purchased from Creative Biolabs.

Techniques: Synthesized, Expressing, Binding Assay

mouse recombinant cd25 Search Results

Image Search Results